Before being an appetite suppressant, it is a medication for diabetes.
The problem is not the margin Novo Nordisk makes on an appetite suppressant, contrary to what the headline says.
The twofold problem is the margin on a diabetes drug, which weighs heavily on patients and health insurers around the world. And the potential supply problems for diabetics, when a vital drug is sold as a miracle weight-loss remedy.
To take things a step further, the only smart male on board is an orange cat.